Charles River, WuXi PharmaTech CEOs Issue Joint Appeal For Shareholder Support
This article was originally published in The Pink Sheet Daily
Executive Summary
A shadow of suspense is expanding during the countdown to the dual shareholder meetings, since a New York-based money management firm that holds 7 percent of Charles River stock called for the abandonment of the merger plan weeks after it was unveiled in April..
You may also be interested in...
Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
BEIJING - A New York-headquartered money management outfit that is the largest shareholder in Charles River Laboratories International has unexpectedly thrown up a potential blockade in the drug research firm's $1.6 billion proposal to acquire China's WuXi PharmaTech
WuXi PharmaTech Founder Ge Li Says Upcoming Merger With Charles River Is Part Of Globalization Of The Drive To Save Lives
BEIJING - The chief executive officer of Shanghai-headquartered WuXi PharmaTech, Ge Li, said that a planned merger with Massachusetts-based contract research organization Charles River could help spark a "revolution" in early-stage drug research in China
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.